Fondazione Arianna Anticoagulazione

Venous thromboembolism associated with COVID-19: therapeutic management and long-term outcomes outlined

A new study by Arianna Anticoagulation Foundation suggests that patients with COVID-19-associated venous thromboembolism may not require prolonged anticoagulant therapy, with a limited duration of 3-6 months being adequate for most patients. The START2-COVID-VTE observational study found low rates of thrombotic recurrences in both groups.

SourceFondazione Arianna Anticoagulazione·JournalResearch and Practice in Thrombosis and Haemostasis·TypeObservational study·DateMay 3, 2023

Exertional dyspnea: a misleading presentation of pulmonary embolism

A recent study published in the Journal of Thrombosis and Haemostasis found that exertional dyspnea can be a misleading presentation of pulmonary embolism, affecting 32% of patients under 75. The Pulmonary Embolism Dyspnea Italian Study (PEDIS) highlighted the importance of evaluating young patients with severe respiratory fatigue for ...

SourceFondazione Arianna Anticoagulazione·JournalJournal of Thrombosis and Haemostasis·TypeObservational study·DateJan 24, 2023

Venous thromboembolism: Less recurrencies with low-dose apixaban compared to discontinuation of the anticoagulant after negative D-dimer

Patients with a history of unprovoked venous thromboembolism who stop treatment after negative D-dimer tests experience an eight-fold increased risk of recurrence compared to those on low-dose apixaban. Low-dose apixaban was found safe and effective for these patients

SourceFondazione Arianna Anticoagulazione·DateMay 20, 2022